Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes

Analysis of RCT (n=4,744) found that, when added to standard therapy in patients with heart failure with reduced ejection fraction, dapagliflozin significantly reduced the risk of worsening heart failure or cardiovascular death independently of diabetes status.

SPS commentary:

A related editorial states that widespread application of the results of the DAPA-HF trial should directly improve clinical outcomes for patients with heart failure, but the observation of benefit for the patients without diabetes may have the most far-reaching implications. There has been longstanding interest in the potential for benefit from SGLT2 inhibition in patients without diabetes, and the data from the DAPA-HF trial support this notion. SGLT2 inhibitors are evolving into a cardioprotective therapy that incidentally lowers blood glucose. Initially developed for the treatment of patients with diabetes, it may be that patients with heart disease or kidney disease have at least as much to gain. A large new body of research is now required to define the full potential of this class for patients without diabetes.


Journal of the American Medical Association

Resource links: